HELX
Franklin Genomic Advancements ETF·CBOE
--
--(--)
--
--(--)
Key Stats
Assets Under Management
22.75MUSD
Fund Flows (1Y)
7.79MUSD
Dividend Yield
0.41%
Discount/Premium to NAV
0.09%
Shares Outstanding
650.00K
Expense Ratio
0.50%
About Franklin Genomic Advancements ETF
Issuer
Franklin Advisers, Inc.
Brand
Franklin
Inception Date
Feb 25, 2020
Structure
Open-Ended Fund
Index Tracked
--
Management Style
Active
Dividend Treatment
Distributes
Distribution Tax Treatment
Qualified dividends
Income Tax Type
Capital Gains
Max ST Capital Gains Rate
39.60%
Max LT Capital Gains Rate
20.00%
Primary Advisor
Franklin Advisers, Inc.
Distributor
Franklin Distributors LLC
HELX invests in global companies benefitting from the advancements of genomic-based research techniques and technologies that are designed to extend or enhance the quality of life. The fund advisor uses fundamental research to identify and select stocks they feel best positioned to capitalize on such genomic advancements. Companies may include those that research, develop, produce or manufacture bionic devices, molecular medicine, pharmaceuticals and agricultural applications. HELX is one of the first three thematic funds to launch from Franklin Templeton.
Classification
Asset Class
Equity
Category
Sector
Focus
Theme
Niche
Genomic Advancements
Strategy
Active
Geography
Developed Markets
Weighting Scheme
Proprietary
Selection Criteria
Proprietary
Returns
1-Month | 3-Month | YTD | 1-Year | 3-Year | 5-Year | |
|---|---|---|---|---|---|---|
Price Performance | -8.21% | +1.03% | -3.45% | +12.48% | +7.97% | -32.36% |
NAV Total Return | -8.60% | -0.15% | -5.79% | +11.90% | +7.81% | -30.94% |
Ratings
No data is currently available
Ainvest’s AI-powered ETF Scoring Algorithm, built to help retail investors make smarter, data-driven decisions. Leveraging deep learning, reinforcement learning, and large language models, the algorithm scores ETFs across five key dimensions: Fund Flow, Momentum, Safety, Fundamentals, and Performance. Each factor is weighted by its correlation to future returns, resulting in a single, actionable score. Backtested over five years with consistently strong predictive accuracy. Ainvest brings institutional-grade artificial intelligence to everyday investors—transforming complexity into clarity with every score.
Holdings Analysis
Sector
Healthcare
97.13%
Basic Materials
2.23%
Technology
0.64%
Healthcare
97.13%
Basic Materials
2.23%
Technology
0.64%
Asset
Region
91.71%
4.58%
3.71%
Category
Ratio
North America
91.71%
Europe
4.58%
Asia
3.71%
Investment Style
Mega
Large
Medium
Multi
Small
Value
Blend
Growth
Multi-Cap Growth
Comprises companies of multiple sizes that have high growth potential. These ETFs focus on firms across different market caps with promising growth prospects.
Top 10 Holdings
Symbol
Ratio
GH
Guardant Health
6.91%
NTRA
Natera
6.29%
KRYS
Krystal Biotech
5.29%
MEDP
Medpace Holdings
4.48%
INSM
Insmed
4.01%
UTHR
United Therapeutics
3.60%
ADPT
Adaptive
3.55%
BBIO
BridgeBio Pharma
3.48%
SAMSUNG BIOLOGICS CO LTD
3.38%
LGND
Ligand
3.25%
Top 10 Weight 44.24%
65 Total Holdings
Is SPY better than HELX?
Dividends
Dividend Payout History
Declaration Date | Record Date | Payment Date | Amount |
|---|---|---|---|
| 2025-12-30 | 2025-12-30 | 2026-01-08 | 0.143 |
| 2021-12-30 | 2021-12-31 | 2022-01-07 | 0.004 |
| 2021-12-13 | 2021-12-14 | 2021-12-21 | 0.114 |
| 2020-12-14 | 2020-12-15 | 2020-12-23 | 0.052 |
How Much Does HELX Pay in Dividends?
Premium/Discount Chart
Assets Under Management
Should I buy HELX?
Fund Flows
